CRIS Current Research Information System

LANZA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.436
NA - Nord America 2.906
EU - Europa 1.972
SA - Sud America 648
AF - Africa 138
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.108
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.814
CN - Cina 2.182
SG - Singapore 2.143
IT - Italia 763
VN - Vietnam 747
HK - Hong Kong 617
BR - Brasile 498
KR - Corea 357
DE - Germania 236
GB - Regno Unito 231
IN - India 162
SE - Svezia 131
NL - Olanda 118
RU - Federazione Russa 77
AR - Argentina 75
JP - Giappone 73
IE - Irlanda 72
FR - Francia 64
UA - Ucraina 50
FI - Finlandia 45
CA - Canada 44
CH - Svizzera 39
CI - Costa d'Avorio 37
MX - Messico 37
ID - Indonesia 36
BG - Bulgaria 33
ZA - Sudafrica 31
BD - Bangladesh 21
EC - Ecuador 21
ES - Italia 21
IQ - Iraq 19
PL - Polonia 18
TG - Togo 17
TR - Turchia 17
AT - Austria 16
EE - Estonia 16
JO - Giordania 15
CL - Cile 14
PY - Paraguay 12
NG - Nigeria 11
SC - Seychelles 11
VE - Venezuela 10
CO - Colombia 8
MA - Marocco 8
AE - Emirati Arabi Uniti 7
BE - Belgio 7
GR - Grecia 7
KE - Kenya 7
PK - Pakistan 7
LT - Lituania 6
EG - Egitto 5
UZ - Uzbekistan 5
AU - Australia 4
MY - Malesia 4
NP - Nepal 4
PE - Perù 4
SN - Senegal 4
TN - Tunisia 4
AL - Albania 3
AZ - Azerbaigian 3
BY - Bielorussia 3
KZ - Kazakistan 3
TH - Thailandia 3
UY - Uruguay 3
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
IS - Islanda 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
RO - Romania 2
XK - ???statistics.table.value.countryCode.XK??? 2
BB - Barbados 1
BS - Bahamas 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DM - Dominica 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GY - Guiana 1
HU - Ungheria 1
IR - Iran 1
JM - Giamaica 1
LB - Libano 1
LI - Liechtenstein 1
LV - Lettonia 1
MU - Mauritius 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 12.108
Salva come PNG Salva come JPEG
Città #
Singapore 1.283
Hefei 805
Hong Kong 615
Beijing 411
Seoul 353
Ashburn 347
Boardman 293
Santa Clara 244
Ho Chi Minh City 171
Fairfield 170
Southend 166
Hanoi 143
Los Angeles 120
Chandler 105
Bologna 103
Dallas 91
Houston 79
Woodbridge 77
Dublin 72
Bengaluru 71
Wilmington 67
Frankfurt am Main 66
Seattle 66
Tokyo 65
Milan 63
Ann Arbor 61
New York 55
Cambridge 51
Princeton 46
São Paulo 45
Buffalo 43
Dong Ket 39
Abidjan 37
Shanghai 34
Sofia 33
Rome 32
Florence 31
Guangzhou 29
Munich 29
Bern 28
Chicago 28
Helsinki 28
Tongling 28
Da Nang 25
Jacksonville 25
Redondo Beach 25
Padova 24
Jakarta 22
Turin 22
Nuremberg 21
Ha Long 20
Haiphong 19
Nanjing 19
Zhengzhou 19
Biên Hòa 17
Lomé 17
Rio de Janeiro 17
Westminster 17
Amman 15
Quận Bình Thạnh 15
Toronto 15
Changsha 14
Mexico City 14
Naples 14
Warsaw 14
Bắc Ninh 13
Xi'an 13
Brasília 12
Ninh Bình 12
Phoenix 12
Shenyang 12
Tianjin 12
Arezzo 11
Genoa 11
Hải Dương 11
Jinan 11
Lappeenranta 11
San Francisco 11
Shijiazhuang 11
Thái Nguyên 11
Atlanta 10
Berlin 10
Castel Maggiore 10
Chennai 10
Falkenstein 10
Forlì 10
Fort Worth 10
Hangzhou 10
Orem 10
Redmond 10
Saint Petersburg 10
Stockholm 10
Wuhan 10
Bắc Giang 9
Guayaquil 9
Montreal 9
Mumbai 9
Abeokuta 8
Amsterdam 8
Bremen 8
Totale 7.497
Salva come PNG Salva come JPEG
Nome #
Stem Cells 324
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 244
A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. 224
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 219
A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. 214
Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. 208
Cellule staminali. Embrionali, mesenchimali, emopoietiche, intestinali, cardiovascolari, muscolari, nervose e placentari 199
A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. 171
Umbilical cord blood CD34(+)cell-derived progeny produces human leukocyte antigen-G molecules with immuno-modulatory functions. 158
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 154
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 153
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 138
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 137
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. 135
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 133
European Data on Stem Cell Mobilization with Plerixafor in Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Multiple Myeloma Patients. A Subgroup Analysis of the European Consortium of Stem Cell Mobilization. 129
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 124
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 122
Novel insights and therapeutic approaches in secondary AML 121
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia 118
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 116
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy 116
CD22 expression in b-cell acute lymphoblastic leukemia: Biological significance and implications for inotuzumab therapy in adults 109
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model 106
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 106
Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT 104
New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders 104
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. 104
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria 103
Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management 103
Five‐Year Real‐World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B‐Cell Precursor Acute Lymphoblastic Leukemia 102
Description of 18 PNH patients with prevalent GPI‐deficient monocytes. An Italian survey 101
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 100
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin 100
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. 100
Vinciamo la vita. Oltre la cura il benessere. Un percorso di lungo periodo nell'alleanza medico paziente-famiglia. 98
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo italianoTrapianto di Midollo Osseo. 98
null 97
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study 96
Pharmacological inhibition of wip1 sensitizes acute myeloid leukemia cells to the mdm2 inhibitor nutlin-3a 95
Development of adaptive immune effector therapies in solid tumors 91
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 90
Efficacy and Safety of Biosimilar Candidate ABP 959 As Compared with Eculizumab Reference Product in Paroxysmal Nocturnal Hemoglobinuria 90
A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) 87
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 86
Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions 84
Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy 84
Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 83
Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 82
null 81
Results of the 6-Year Follow- up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia 80
Alloreactivity: the Janus-face of hematopoietic stem cell transplantation 79
PNH CLONES PREVALENCE STUDY IN PH-NEGATIVE MYELOPROLIFERATIVE DISORDERS 78
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 78
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation 78
null 77
null 76
The Circular Life of Human CD38: From Basic Science to Clinics and Back 75
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 75
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study 74
Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia 73
RISK-ADAPTED MRD-DIRECTED THERAPY FOR YOUNG ACUTE MYELOID LEUKEMIA ADULTS: 6-YEAR UPDATE OF THE GIMEMA AML1310 TRIAL 68
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 68
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach 68
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study 67
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 66
Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study 65
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 63
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 61
Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi Phase 2 Study 59
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 56
The oldest case of lymphoma? Insights from a XIII century fresco 52
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 51
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS 50
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency 49
Novel approaches for hematopoietic stem cell mobilisation and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose 49
Ibrutinib: from bench side to clinical implications 49
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status 48
Allogeneic transplantation for AML aged>= 70 years. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 48
Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders 45
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation 44
Isolamento e caratterizzazione immunofenotipica di cellule non-emopoietiche presenti in versamenti ascitici e pleurici di pazienti con malattie ematologiche 42
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 42
Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis 42
A report from the SIdEM: Italy 41
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment 40
CD123 (Interleukin 3 receptor a chain) 40
Cytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders 39
Cellule staminali circolanti in pazienti con infarto miocardico 39
Issue highlights—November 2024 39
Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders 39
Thrombocytosis in systemic lupus erythematosus: a possible clue to autosplenectomy? 37
Growing adoption of pharmacologic maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf of the EBMT acute leukemia working party 36
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients 36
Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection 35
Cellule staminali circolanti in pazienti con infarto miocardico 35
In Memoriam of Riccardo Saccardi (Careggi University Hospital, Florence), eminent hematologist and a remarkable innovator in the treatment of autoimmune diseases by means of novel methodologies in HSC transplantation 35
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia 34
Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT 34
Flow cytometric immunophenotyping of acute lymphoblastic leukemia : is the time ready for consensus guidelines ? 34
Totale 9.029
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.062
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.062
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021262 0 0 0 0 0 11 1 33 43 15 23 136
2021/2022500 79 3 31 29 40 30 18 35 14 50 99 72
2022/2023932 50 69 35 61 34 37 12 149 165 132 92 96
2023/2024650 35 61 66 58 75 93 36 50 34 64 38 40
2024/20253.897 91 272 318 208 591 144 403 95 121 326 340 988
2025/20265.470 1.012 1.548 1.086 859 691 274 0 0 0 0 0 0
Totale 12.570